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Abstract The human hepatitis B virus X protein (HBx) is
known as a dual-specificity transactivator stimulating the
transcriptional machinery in the nucleus and signal transduction
pathways in the cytoplasm. HBx-induced activation of mitogen-
activated protein kinase (MAPK) signaling cascades is consid-
ered to play an important role in hepatitis B virus-mediated
hepatocarcinogenesis. Herein, we have identified the regions of
HBx that are crucial for activating such signaling cascades in
vivo. A truncated mutant incorporating regions C^E (amino
acids 58^140) was as effective as the full-length HBx in
activating MAPKs and enhancing activator protein-1 binding
activity. While deletion of region C (amino acids 58^84) or D
(amino acids 85^119) led to a drastic loss of function, region E
(amino acids 120^140) was dispensable for the activation of
signaling cascades. Overall, these findings provide the first
evidence for the requirement of domain 58^119 of HBx in
transmitting mitogenic signals to the nucleus in vivo. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Persistent infection by hepatitis B virus (HBV) often leads
to hepatocellular carcinoma by a yet unknown mechanism [1].
Nonetheless, the 154 residue long polypeptide hepatitis B vi-
rus X protein (HBx), encoded by HBV, is an important etio-
logical factor in viral carcinogenesis [2]. Comprehensive stud-
ies show HBx is a pleiotropic transcriptional transactivator
[2]. Besides the cognate HBV promoter, HBx transactivates
transcription from a diverse range of viral and cellular pro-
moters, such as long terminal repeats of human immunode¢-
ciency and Rous sarcoma virus [3,4], the promoters of proto-
oncogenes [5^7] and host RNA polymerase II and III
promoters [8,9]. As HBx does not bind to double-stranded
DNA, such broad gene-regulatory functions are attributed
to protein^protein interactions with other cellular factors.
Consistently, HBx is shown to directly interact with a multi-
tude of nuclear proteins such as speci¢c components of the
basal transcription machinery [10], the bZip family of tran-
scription factors [11], tumor suppressor factor p53 [12], and
UV-damaged DNA binding protein [13]. Alternatively, HBx
manifests its transactivation function by modulation of signal-
ing cascades involving mitogen-activated protein kinases
(MAPKs) [14], Src-dependent kinases [15], protein kinase C
[16], and Jak1-STAT pathways [17]. HBx-mediated transacti-
vation functions are therefore so diverse that a unifying mech-
anism of its action remains elusive. Nevertheless, a dual mode
of HBx action has been demonstrated in accordance with its
both nuclear and cytoplasmic localization [18,19]. Thus HBx
acts as both a nuclear and a cytoplasmic transactivator; while
nuclear HBx a¡ects transcription directly by interacting with
speci¢c transcriptional machinery at the promoter level, the
cytoplasmic HBx in£uences indirectly by modulating various
intracellular signaling [18]. Furthermore, the ¢nding that a
variant of HBx engineered to relocate exclusively to the nu-
cleus via a nuclear localization signal (HBx-NLS) fails to ac-
tivate cytoplasmic signaling cascades, but, in contrast, fully
retains its nuclear activity in stimulating HBV enhancer I,
implies that the nuclear and cytoplasmic activities of HBx
are independent functions [18] and may involve di¡erent do-
mains of HBx. The regions of HBx involved in its interaction
with a number of nuclear proteins have been mapped [2,10^
13]. We have identi¢ed a region on HBx encompassing resi-
dues 58^140 as the minimal nuclear transactivation domain
[20]. However, in sharp contrast, the structure^function stud-
ies on its cytoplasmic activities lack such extensive investiga-
tion under in vitro and in vivo settings.
Exploiting the membrane-fusogenic ability of Sendai-viral
F-glycoprotein and high a⁄nity of terminal L-galactose con-
taining ligands (present on F-glycoprotein) for asialoglycopro-
tein receptor on the hepatocyte surface, we have developed an
e⁄cient viral-based delivery system (F-virosomes1) to transfer
foreign genes to hepatocytes both in vitro and in vivo [21^24].
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Using this system, we have recently established a role of HBx
in activating cytoplasmic MAPK signaling cascades in normal
adult hepatocytes and discerned such activation to be func-
tionally important for HBx-mediated hepatocellular carcino-
ma (submitted). In this study, we examined the e¡ects of
various HBx mutants on mitogenic signal transduction path-
ways and identi¢ed for the ¢rst time its domain crucial for
such activities in liver cells in vivo.
2. Materials and methods
2.1. Expression vector of HBx and its mutants
Using the full-length HBV template (adw subtype) and the follow-
ing oligonucleotide primers: forward, 5P-CGGAATTCATGGCTGC-
TAGGCTGT-3P (X0f ) and reverse, 5P-CGGAATTCTTAGGCAGA-
GGTGAAAAAG-3P (X0r), the HBx gene was ampli¢ed as described
earlier [20]. This cDNA (a 471-bp EcoRI fragment of the HBx gene,
henceforth called X0) was cloned into plasmid vector pSG5 under the
control of the SV40 promoter (Stratagene). Deletion mutants of X0
(X7, X9 and X10) were constructed by site-directed mutagenesis using
single-stranded X0 template. The truncated form X15 was constructed
by PCR using the following primer: forward, 5P-CGGAATTCCA-
TATGCTCCCCGTCTGTGCCTTC-3P (X15f ) and reverse, 5P-CGG-
AATTCGGATCCTTATTTGTGCCTACAGCCTCCTAA-3P (X15r)
and cloned into pSG5. All plasmids were isolated using the Qiagen
Megaprep kit.
2.2. Administration of DNA-loaded virosomes, insulin and PD98059
into mice
X0 or its mutant DNAs were loaded inside F-virosomes following
our published methodologies [24]. Female BALB/c mice (12 weeks
old) weighing V18 g were injected i.v. into the tail vein with 2 Wg
each of DNA-loaded virosomes and kept for 48 h before being killed.
20 Wg of insulin (Sigma) in phosphate-bu¡ered saline (PBS) was in-
jected i.v. into mice 1 h prior to death. Intravenous administration of
PBS containing 75 WM PD98059 (New England Biolabs) in 0.37%
dimethyl sulfoxide (DMSO) was injected 5 h before the X0/insulin-
injected mice were killed. Injection of PBS alone (mock injection),
pSG5 vector DNA-loaded F-virosomes and PBS with 0.37% DMSO
served as appropriate negative controls. During all experiments, Delhi
University guidelines were followed and animals were kept under
standard pathogen-free conditions and were provided food and water
ad libitum. Liver biopsies from animals were carried out as described
below. A portion of each liver was kept frozen separately for isolating
total RNA and preparing nuclear extracts. Each experiment was car-
ried out at least three times independently.
2.3. Monitoring expression of HBx and its mutants
Separation of parenchymal cells (hepatocytes) was accomplished as
described by us earlier [24]. Hepatocytes free from detectable red
blood cells were collected and immediately stored at 370‡C until
use. Total RNA was isolated from hepatocytes using Trizol (Gibco-
BRL). The primer sets designed for X0 and its mutants were as fol-
lows: for X0 and X15 speci¢c transcripts X15f and X15r ; for X7 and
X9 transcript, X0f and X15r ; for X10 transcript, X15f and X0r. Gene-
speci¢c ‘antisense’ primers were employed for reverse transcription
using DNase I (Gibco-BRL)-treated RNAs and Superscript1 RNase
H3 reverse transcriptase (RT) (Gibco-BRL). PCR ampli¢cation (35
cycles) of the RT products was performed using high ¢delity Platinum
Taq DNA Polymerase (Gibco-BRL) with a cycling pro¢le of 94‡C for
45 s, 62‡C for 45 s (or 55‡C for 45 s in the case of L-actin primers,
Stratagene), 72‡C for 1 min and ¢nal extension at 72‡C for 10 min.
Speci¢c ampli¢ed products of length 270 bp for X0 and X15, 351 bp
for X7, 321 bp for X9 and 228 bp for X10 DNA were visualized by
ethidium bromide staining on a 1.5% agarose gel. As an internal
control, L-actin mRNA was also ampli¢ed by RT-PCR for each sam-
ple and a product of 650 bp was obtained. Speci¢city of the RT-PCR
products was further ensured by Southern hybridization using a
32P-labelled X0 DNA fragment as the probe.
2.4. ERK assay
Standard published protocols [14] were followed for the extracellu-
lar signal-regulated kinase (ERK) assay with some modi¢cations. To
summarize, hepatocytes were lysed in a bu¡er composed of 20 mM
Tris^HCl (pH 7.5), 150 mM NaCl, 1.0% Triton X-100, 10% glycerol,
1 mM dithiothreitol, 1 mM NaF, 1 mM Na3VO4, 20 mM p-nitro-
phenyl phosphate, 50 mM L-glycerol phosphate, 1 mM EGTA, 2 mM
phenylmethylsulfonyl £uoride, 1.5 mM MgCl2 and 20 Wg/ml each of
aprotinin and leupeptin (Sigma) in conjunction with Complete1 pro-
tease inhibitor cocktail (Roche). Protein concentration in the lysates
was estimated by the Bradford assay. ERK/MAPK activity was moni-
tored by in vitro phosphorylation of exogenous substrate myelin basic
protein (MBP) (Gibco-BRL). In brief, 5 Wg each of protein lysate was
included in a reaction containing 5 Wg MBP in kinase bu¡er (20 mM
Tris^HCl, pH 7.5, 40 mM MgCl2, 10 WM ATP (Sigma)) and 2 WCi [Q-
32P]ATP (Amersham Pharmacia Biotech) and incubated for 30 min at
30‡C. The reaction was stopped by the addition of Laemmli sample
bu¡er and resolved on 15% SDS^PAGE. The upper half of the gel
was subjected to Western analysis with anti-ERK antibody (Santa
Cruz Biotechnology) and was developed by the ECL detection system.
The lower half of the gel containing MBP protein was dried and
exposed to X-ray ¢lms. To check for equal amounts of MBP in
each lane, dried blots were stained by Coomassie blue (CB). The
stained bands corresponding to MBP protein were excised and radio-
activity was measured by liquid scintillation counting to calculate fold
activation.
2.5. Detection of phosphorylated ERK and JNK by Western blotting
The levels of active (phosphorylated) forms of ERK (P-ERK) and
c-Jun N-terminal kinase (P-JNK) in the hepatocyte cell extracts (5 Wg)
were resolved in 15% SDS^PAGE and subjected to immunoblotting
with anti-phospho-p44/42 MAPK antibody and Phospho Plus0
SAPK/JNK Antibody (Cell Signaling Technology) respectively. The
corresponding blots were stripped and reprobed with anti-ERK and
anti-JNK antibodies.
2.6. Preparation of nuclear extracts and gel mobility shift assay
Nuclear extracts from each liver lobe and HepG2 cells were pre-
pared as described by Lassar et al. [25]. Electrophoretic mobility shift
assays (EMSA) were carried out essentially following a published
protocol [14]. The synthetic oligonucleotides used as a probe or com-
petitor DNA in this assay consist of a double-stranded TRE sequence
(Promega). Binding reactions with 36 Wg of liver nuclear extracts or
6 Wg of HepG2 cell extracts were done using 10 000 cpm of 32P-labeled
probe for 60 min at 4‡C followed by incubation for 5 min at 25‡C.
Competition binding experiments were performed with 50-fold molar
excess of unlabeled oligonucleotide. The reaction mixtures were re-
solved on 4% non-denaturing polyacrylamide gel, dried and visualized
by autoradiography. For antibody-supershift studies, 4 Wg of antise-
rum (Santa Cruz Biotechnology) to either c-Jun/c-Fos or normal IgG
was added after completion of the binding reaction and incubated at
28‡C for 20 min. Some nuclear extracts (70 Wg) were subjected to 15%
SDS^PAGE followed by Western blotting to detect c-Jun and c-Fos
protein levels using speci¢c antibodies (Santa Cruz Biotechnologies)
and visualized by ECL detection.
3. Results
3.1. Basis for selecting HBx mutants
Based on sequence homology with other mammalian he-
padnaviruses, the HBx sequence (154 amino acids) has been
divided into six regions (A^F) (Fig. 1). Earlier, we had con-
structed a panel of HBx mutants and demonstrated that dele-
tions of regions A, B, and F could not abrogate the HBx-
mediated transactivation of the Rous sarcoma virus long ter-
minal repeat (RSV-LTR). On the other hand, deletion of re-
gions C, D, and E resulted in signi¢cant loss of activity. Fur-
ther, a truncated mutant, X15 harboring only regions C^E
(amino acids 58^140), was able to stimulate RSV-LTR quite
e⁄ciently, suggesting an important role of residues 58^140 of
HBx in RSV-LTR transactivation [20]. Considering that HBx-
mediated transactivation occurs via a dual mechanism, we
investigated whether the same domain of HBx is required
for activating the MAPK pathways. Based on this rationale,
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we selected a truncated mutant containing regions C^E (X15)
as well as deletion mutants which were lacking either region C
(X7), D (X9) or E (X10) and analyzed their transactivation
potential in signaling cascades.
3.2. In vivo ERK activity of HBx mutants in mouse hepatocytes
We recently demonstrated that HBx expressed in vivo in
mouse hepatocytes is able to activate ERKs constitutively
resembling an oncogenic stimulus in function (submitted).
Considering the central importance of ERK activation in tu-
mors [26], it is pertinent to identify the region(s) of HBx in-
volved in such activities. Thus expression vectors X0, X7, X9,
X10, and X15 were delivered to mouse liver through F-viro-
somes (Fig. 2). Insulin, a well-known stimulator of ERK via
Ras-Raf-MAPK cascades [27], was injected into mice to serve
as a positive control (Fig. 2a,b, lanes 9 and 10). The cytostatic
drug PD98059 [28], known to be a speci¢c and e⁄cient inhib-
itor of MAP kinase kinase kinase (MEK), the kinase that
activates ERKs, was introduced into mouse liver to determine
the requirement of MEK in HBx-mediated ERK activation
(Fig. 2a,b, lanes 4 and 10). Hepatocyte lysates were analyzed
for the phosphorylation of ERK1/2 as well as for in vitro
kinase assay using MBP as the speci¢c substrate (Fig. 2a,b).
Consistent with our previous results [20], X15-expressing he-
patocytes showed an elevated level of phosphorylated ERK
along with an increased ERK functional activity over that of
X0 (see lane 8 against lane 3), which can be accounted for by
the deletion of the N-terminal trans-repression domain of
HBx in X15 [29]. In contrast to X0, both X7 and X9 mutants
showed drastic inhibition of phosphorylation in ERK1/2 pro-
teins (Fig. 2a, upper panel, compare lanes 5 and 6 with lane
3), and also were poor activators of MBP phosphorylation
(only 10^20% activity of X0) (Fig. 2b, upper panel, lanes 5
and 6). X10 mutant displayed 80% activity of full-length HBx
protein (X0) in both assays (Fig. 2a,b, upper panels, lane 7).
Interestingly, all the mutants exhibited total ERK levels com-
parable to vector and X0, eliminating the possibility of ERK
levels contributing to variations in their activities (Fig. 2a,b,
lower panels). In addition, equal protein loading in all lanes
hereafter was veri¢ed by Ponceau S red staining (data not
shown). Moreover, the presence of speci¢c transcripts of all
the HBx mutants, as checked by RT-PCR (Fig. 2d, upper
panel) followed by Southern hybridization (data not shown),
excluded the possibility of di¡erent activities exhibited by
HBx mutants to be related to gene expression. A drastic
loss of activity in both X7 and X9 thus suggests the essential
requirements of regions C and D (amino acids 58^84 and 85^
119) in HBx-mediated ERK activation. In conclusion, reten-
Fig. 1. Scheme of HBx mutants. Based on the homology with other
mammalian hepadnaviruses, the 154 amino acids long wild-type
(WT) HBx sequence (X0) has been divided into six regions (A^F).
Deletion (v) mutants (X7, X9, X10) and a truncated mutant (X15)
of HBx are shown schematically. A solid bar indicates the portion
of HBx present in the mutant, with the deleted region shown as a
gap. The light vertical lines depict the boundaries of the six regions
of homology (A^F).
Fig. 2. E¡ect of HBx mutant genes on MAPK activity in vivo. a:
Hepatocyte lysates (5 Wg) were prepared 2 days after injection of
X0, X7, X9, X10 and X15 DNA-loaded virosomes into mice as de-
scribed in the text. Immunoblotting with anti-phospho-ERK anti-
body is shown in the upper panel and with anti-ERK antibody is
shown in the lower panel. b: The pro¢le of MBP phosphorylation
(upper panel), CB-stained MBP (middle panel) and total ERK level
(lower panel) was analyzed as described in the text. c: Fold activa-
tion in terms of MBP phosphorylation was calculated as described
in the text. d: The expression of HBx and its mutants (upper panel)
and the L-actin mRNA (lower panel) were examined as narrated in
the text. Primers used: for X0 and X15, X15f and X15r ; for X7
and X9, X0f and X15r ; for X10, X15f and X0r.
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tion of complete activity in X15 comprising regions C, D, and
E de¢nes residues 58^140 of HBx as the minimal functional
domain involved in ERK activation.
3.3. Regions of HBx involved in JNK activation
The JNKs are another important member of the MAPK
family of proteins that are activated by stress and growth
factors [30]. As our recent studies showed the role of HBx
in activating JNKs in mouse liver, we further attempted to
identify the domain(s) of HBx involved in their activation. We
assessed the levels of phosphorylated JNKs in the hepatocytes
expressing HBx and its mutants as above. Untreated and UV-
treated 293 cells were used as negative and positive controls
respectively (lanes 1 and 2). As shown in Fig. 3, upper panel,
HBx mutants in£uenced JNK activation in a pattern consis-
tent with ERK activation. X15, which includes regions C^E
(amino acids 58^140), displayed increased levels of P-JNK,
even higher than that induced by X0 (compare lanes 3, 4
and 8). While X7 and X9 mutants showed P-JNK levels com-
parable to that of vector (compare lane 3 with lanes 5 and 6),
X10 exhibited activity close to that of X0 (compare lane 7
with lanes 3 and 4). The total JNK level remained the same
for all the lysates, re£ecting that the variations observed in
JNK activities are not the consequences of changes in JNK
expression levels (Fig. 3, lower panel, lanes 3^8). Taken to-
gether, these results show that the minimal functional domain
of HBx required for JNK activation also converges to residues
58^140.
3.4. Minimal functional region(s) of HBx involved in increased
DNA binding potential of AP-1 in vivo
The activator protein-1 (AP-1) family of transcription fac-
tors are activated by the integrated e¡ects of activated ERKs
and JNKs [30]. In accordance with this, we next questioned
whether HBx-mediated enhanced AP-1 activity involves
MAPK activation. Nuclear extracts prepared from the liver
lobes from injected animals as used previously (Figs. 2 and 3)
were allowed to bind to radiolabelled AP-1 DNA (Fig. 4a,
panel i). Serum-starved and serum-induced HepG2 nuclear
extracts contributed as controls for the induction of AP-1
binding activity (lanes 8 and 9). As apparent, both X7 and
X9 mutants of HBx showed a marked mitigation of AP-1
activity almost comparable to the baseline (compare lanes 1,
4 and 5). By contrast, X10 displayed enhanced activity, albeit
less than X0 (lanes 3 and 6), while the truncated mutant X15
with region C^E of HBx was as e¡ective as the full-length
HBx (compare lanes 3 and 7). To assess the speci¢city of
the AP-1 binding complex, a supershift assay was also per-
formed (Fig. 4a, panel ii). Addition of antibody to c-Jun and
c-Fos to the nuclear extracts resulted in ‘supershifted’ com-
plexes. The results on AP-1 binding activity were supported
further by respective levels of c-Jun and c-Fos (Fig. 4b,c,
panel i). Speci¢cally, we found that both X7 and X9 mutants
showed c-Jun and c-Fos protein levels close to basal (compare
lane 1 with lanes 3 and 4). While X10 induced c-Jun and
c-Fos levels comparable to X0 (lanes 2 and 5), X15 stimulated
both c-Jun and c-Fos over X0 (lanes 2 and 6). The levels of
c-Jun and c-Fos observed in various mutants thus validated
the observed AP-1 binding activity. Overall, these results are
in parallel to those obtained from the mutants’ in£uence on
ERK and JNK activation. Altogether, they suggest that the
minimal functional region of HBx (amino acids 58^140) re-
quired for enhanced AP-1 binding activity converges to the
region needed for both ERK and JNK activation.
4. Discussion
HBx is unique among viral transactivators as it can modu-
late gene expression by a dual mechanism, viz. by directly
in£uencing the transcription apparatus and also by acting
upon various signal transduction pathways. Although the mo-
lecular mechanism of its mode of interference into the tran-
scription machinery has been well investigated, the mechanism
by which it stimulates various signaling cascades is not
known. Recently, we have established, in vivo, that HBx is
a potent activator of MAPK pathways in mouse liver (sub-
mitted). In order to have a better understanding of the HBx
transactivation mechanisms, we aimed our present study to
determine the regions of HBx required for activating signaling
cascades. We identi¢ed residues 58^140 of HBx as the mini-
mal functional domain needed for HBx activation of MAPKs
and the subsequent downstream events. Our study thus helped
to delineate the promiscuous transactivation mechanism of
HBx. The additional signi¢cance of our data lies in the fact
that the observations have been made in the natural, physio-
logical environment of hepatocytes, in the whole animal. Con-
sistent with our previous study on HBx transactivation of
RSV-LTR [20], the present work demonstrates that truncated
mutant X15 spanning domains C^E (amino acids 58^140) of
HBx is as e¡ective as the wild-type HBx (X0) in activating
cytoplasmic signaling cascades. Since the functional domain
(amino acids 58^140) of HBx required to activate cytoplasmic
cascades is also essential for activating the transcriptional
machinery [10,11,29,31], it may be inferred that the nuclear
and cytoplasmic transcriptional activation functions of HBx
grossly occur via a common domain. We ¢nd that while dele-
tions involving either region C (X7) or D (X9) resulted in
almost complete loss of function, deleting region E (X10)
only moderately obliterated HBx ability to activate MAPK
cascades. This is apparently in contrast with our previous
studies, where a signi¢cant abrogation of RSV-LTR transac-
tivation occurred by deleting region E [20]. This contradiction
can be consolidated by the fact that the region encompassing
amino acid residues 118^133 of HBx is acidic in nature and is
likely to be essential for HBx nuclear transcriptional activities,
such as its role as coactivator of transcription factors [32].
This would suggest no involvement of this region in transcrip-
Fig. 3. In£uence of HBx mutants on JNK activation. The same
hepatocyte lysates (5 Wg) as described in Fig. 2 were tested for acti-
vated JNK levels (P-JNK, upper panel) and total JNKs (JNK1/2,
lower panel). (3) UV and (+) UV represent total extracts from un-
irradiated and irradiated 293 cells as negative and positive controls
respectively.
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tional activation via cellular signaling cascades. However, re-
gion E of HBx has been shown to bind to the 19S proteasome
complex, which is closely related to the COP9 signalsome, a
complex containing a weak canonical MAPK kinase site
[33,34]. HBx probably binds this complex via region E and
contributes moderately to the activation of MAPK cascades,
thus explaining the partial reduction of activity in X10. These
results therefore demonstrate that while the minimal essential
region of HBx involved in activating MAPK cascades maps to
region 58^119, region E (amino acids 120^140) integrates ad-
Fig. 4. AP-1 DNA binding activity of HBx mutants. a i : EMSA was performed with nuclear extracts (36 Wg for liver extracts and 6 Wg for
HepG2 extracts) prepared as described in the text. (3) and (+) indicate the absence and presence of cold competitor respectively during the
DNA-Protein interaction. ii : Speci¢city of the AP-1 binding was con¢rmed by a ‘supershift’ assay as mentioned in the text. (*) and (**) repre-
sent the supershifted AP-1 complex in the presence of c-Fos (lane 2) and c-Jun antibodies (lane 3) respectively. ‘IgG’ indicates the normal rab-
bit serum taken as negative control. b and c: Nuclear extracts (70 Wg for liver extracts and 30 Wg for HepG2 extracts) were subjected to immu-
noblotting for detection of c-Jun protein and c-Fos protein levels using speci¢c antibody respectively (panel i). Panel ii re£ects equal protein
loading by Ponceau S red staining of the corresponding blots. (3) S and (+) S stand for HepG2 extracts following serum starvation or induc-
tion respectively.
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ditional events to restore the wild-type activity of HBx. Alto-
gether, it may be mentioned that regions C, D, and E (amino
acids 58^140) of HBx are involved in modulating transcrip-
tion through cytoplasmic signaling cascades. This conclusion
is supported by the observations that similar regions of HBx
are involved in activation of the Jak1-STAT signaling path-
way [17] and region 90^122 has been shown to interact with
protein kinase C binding protein (XAP3), presumably facili-
tating HBx to activate the protein kinase C pathway in the
cytoplasm [35].
Importantly, our studies also demonstrate that deletion of
HBx region C (amino acids 58^84) or D (amino acids 85^119)
not only abolishes activation of MAPKs in cytoplasm but also
AP-1 binding activity in the nucleus, thus directly linking
HBx-mediated enhanced AP-1 activity with activation of
MAPKs. These observations suggest that HBx-induced nu-
clear and cytoplasmic e¡ects may not be mutually exclusive
and a cross-talk exists between the two transactivation func-
tions. Studies by Johnson et al. which demonstrate that HBx-
mediated enhancement of both RNA polymerase II- and III-
dependent promoter activities occur through the involvement
of Ras-mediated upregulation of TATA binding protein lend
further support to this view [9]. It may be thus reasoned that
concomitant interactions of HBx with cytoplasmic signal
transduction components and nuclear transcriptional machi-
nery account for HBx transcriptional activation.
Intriguingly, our data demonstrate for the ¢rst time that the
mutational loss or gain of JNK stimulating activity is coupled
with that of ERK activity. This congruent pattern of ERK
and JNK activation makes it reasonable that HBx mediates
activation of both kinases via a common upstream e¡ector.
Based on a recent study of MAPK activation to occur
through JAK tyrosine kinases, via stimulation of Src kinases
and adapter signaling molecules [36], we speculate that HBx-
induced JAK activation serves as a common e¡ector for in-
creased ERK and JNK activities via Src and Ras. Integration
of ERK and JNK activities manifested through elevated c-Fos
and c-Jun levels results in increased binding activity of AP-1
that might lead to increased expression of genes responsible
for cell proliferation and tumorigenesis. Therefore, the present
study, de¢ning the domain of HBx involved in signaling path-
ways, not only helps to dissect the complex mechanism of
HBx transactivation, but also attempts to understand the sig-
ni¢cance of mitogenic cascades in HBV-associated liver carci-
nogenesis in the native hepatocyte environment in vivo.
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